Compare MGM Resorts International (MGM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Novartis AG — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 24.5× MGM Resorts International's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| MGM | NVS | |
|---|---|---|
Market Cap | $11.86B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $168.62 |
52-Week Low | $30.72 | $113.50 |
Enterprise Value | $40.90B | $330.27B |
Dividend Yield | 0.03% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM trades at $45.67, down 1.0% today, with a neutral technical stance and mixed earnings history. The company reported $17.54B revenue in 2025 but net income fell to $206M, with profit margins narrowing. Recent news highlights acquisition interest from Barry Diller at $48.30 per share, creating investor uncertainty. Cash flow trends show improving operational strength, though net cash flow remains negative.
Outlook is balanced: potential upside exists from the acquisition offer and steady revenue, but risks include declining profitability and high debt. Analysts are split evenly between Buy and Hold, with a $48.93 consensus target suggesting modest upside. Investors should weigh takeover prospects against fundamental pressures.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
